- Mollugin
-
- $39.00 / 5mg
-
2025-05-27
- CAS:55481-88-4
- Min. Order:
- Purity: 98%
- Supply Ability: 10g
- Mollugin
-
- $0.00 / 20mg
-
2023-02-24
- CAS:55481-88-4
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- Mollugin
-
- $0.00 / 20mg
-
2023-02-24
- CAS:55481-88-4
- Min. Order: 5mg
- Purity: Analytical Standard
- Supply Ability: 10 g
|
| | MOLLUGIN Basic information |
| | MOLLUGIN Chemical Properties |
| Melting point | 132～134℃ | | Boiling point | 453.2±45.0 °C(Predicted) | | density | 1.239±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Chloroform (Slightly), Ethyl Acetate (Slightly) | | form | Solid | | pka | 8.40±0.40(Predicted) | | color | Yellow to Green |
| Safety Statements | 24/25 | | HS Code | 29329990 |
| | MOLLUGIN Usage And Synthesis |
| Uses | Mollugin is an anti-tumor agent inducing apoptosis and autophagy in various cancer models. | | Definition | ChEBI: Rubimaillin is a benzochromene that is 2H-benzo[h]chromene which is substituted by two methyl groups at position 2, a methoxycarbonyl group at position 5, and a hydroxy group at position 6. Found in the Chinese medical plant Rubia cordifola, It has an anti-cancer effect by inhibition of TNF-alpha-induced NF-kappaB activation. It is also a dual inhibitor of acyl-CoA:cholesterol acyltransferase 1 and 2 (ACAT1 and ACAT2), but is more selective for the ACAT2 isozyme. It has a role as a plant metabolite, an acyl-CoA:cholesterol acyltransferase 2 inhibitor, a NF-kappaB inhibitor, an antineoplastic agent, an apoptosis inducer, a neuroprotective agent and an anti-inflammatory agent. It is a benzochromene, a methyl ester and a member of phenols. | | Biological Activity | Mollugin displays inhibitory activity in arachidonic acid- and collagen-induced platelet aggregation. Mollugin has been reported to inhibit cancer cell proliferation, and has other biological activities including anti-inflammatory and apoptotic effects. | | in vivo | Mollugin (0-75 mg/kg, Orally, three times per week for 36 days) inhibits growth of HeLa cells in a xenograft tumor model[1]. | Animal Model: | BALB/c female athymic nude mice (six-week-old, subcutaneously injected with 0.2 mL HeLa cells)[1] | | Dosage: | 0, 25 and 75 mg/kg | | Administration: | Orally, three times per week for 36 days | | Result: | Suppressed tumor growth, whereas the body weight did not change. Significantly reduced the protein expression of p-p65 and COX-2 in the tumors. |
|
| | MOLLUGIN Preparation Products And Raw materials |
|